- Home
- UHT vs REPL Comparison
UHT vs REPL Comparison
Compare UHT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- REPL
- Stock Information
- Founded
- UHT 1986
- REPL 2015
- Country
- UHT United States
- REPL United States
- Employees
- UHT N/A
- REPL N/A
- Industry
- UHT Real Estate Investment Trusts
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- REPL Health Care
- Exchange
- UHT Nasdaq
- REPL Nasdaq
- Market Cap
- UHT 540.7M
- REPL 578.4M
- IPO Year
- UHT N/A
- REPL 2018
- Fundamental
- Price
- UHT $38.64
- REPL $7.01
- Analyst Decision
- UHT
- REPL Strong Buy
- Analyst Count
- UHT 0
- REPL 6
- Target Price
- UHT N/A
- REPL $20.00
- AVG Volume (30 Days)
- UHT 46.3K
- REPL 1.1M
- Earning Date
- UHT 04-28-2025
- REPL 05-27-2025
- Dividend Yield
- UHT 7.60%
- REPL N/A
- EPS Growth
- UHT 15.38
- REPL N/A
- EPS
- UHT 1.35
- REPL N/A
- Revenue
- UHT $99,725,000.00
- REPL N/A
- Revenue This Year
- UHT N/A
- REPL $31.16
- Revenue Next Year
- UHT N/A
- REPL N/A
- P/E Ratio
- UHT $28.72
- REPL N/A
- Revenue Growth
- UHT 1.03
- REPL N/A
- 52 Week Low
- UHT $34.56
- REPL $4.92
- 52 Week High
- UHT $47.30
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- UHT 47.71
- REPL 34.78
- Support Level
- UHT $38.60
- REPL $6.93
- Resistance Level
- UHT $39.57
- REPL $8.54
- Average True Range (ATR)
- UHT 0.75
- REPL 0.74
- MACD
- UHT 0.08
- REPL -0.13
- Stochastic Oscillator
- UHT 55.07
- REPL 3.52
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.